ImmunityBio, Inc.
IBRXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable. The $8.09B market capitalization puts IBRX squarely in mid-cap range for its industry. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
Market Cap
$8.09B
Beta
0.07
P/E (TTM)
—
P/E (Fwd)
128.67
EPS (TTM)
$-0.85
EPS (Fwd)
$0.06
ROE
—
ROA
-34.4%
Cash
$380.9M
Total Debt
$1.12B
Free CF
-$193.7M
52W Change
190.2%
Annual Financials
Cash vs Debt
On the balance sheet, IBRX has $380.9M in cash with $1.12B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$193.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has grown from $240K (2022) to $113.3M (2025), reflecting a 47103% increase over the period.
IBRX's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for ImmunityBio, Inc. and its sector.